These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16996485)

  • 1. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
    Polzer J; Bangs ME; Zhang S; Dellva MA; Tauscher-Wisniewski S; Acharya N; Watson SB; Allen AJ; Wilens TE
    Biol Psychiatry; 2007 Mar; 61(5):713-9. PubMed ID: 16996485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
    Wernicke JF; Holdridge KC; Jin L; Edison T; Zhang S; Bangs ME; Allen AJ; Ball S; Dunn D
    Dev Med Child Neurol; 2007 Jul; 49(7):498-502. PubMed ID: 17593120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
    Donnelly C; Bangs M; Trzepacz P; Jin L; Zhang S; Witte MM; Ball SG; Spencer TJ
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):176-85. PubMed ID: 20040824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
    Michelson D; Buitelaar JK; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
    J Am Acad Child Adolesc Psychiatry; 2004 Jul; 43(7):896-904. PubMed ID: 15213591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
    Bangs ME; Tauscher-Wisniewski S; Polzer J; Zhang S; Acharya N; Desaiah D; Trzepacz PT; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):209-218. PubMed ID: 18176331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
    Sangal RB; Sangal JM
    Clin Neurophysiol; 2006 Sep; 117(9):1996-2006. PubMed ID: 16890481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
    Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
    J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.